据香港联交所最新数据显示，3月4日，Lazard Asset Management LLC增持国药控股(01099)363.72万股， 每股作价20.6296港元，总金额约为7503.4万港元。增持后最新持股数目约为1.64亿股，持股比例为 12.25%。 ...

智通财经APP获悉，据香港联交所最新数据显示，3月4日，Lazard Asset Management LLC增持国药控股 (01099)363.72万股，每股作价20.6296港元，总金额约为7503.4万港元。增持后最新持股数目约为1.64亿 股，持股比例为12.25%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 董事會會議通告 承董事會命 國藥控股股份有限公司 董事長 晉斌 中國，上海 2026 年 3 月 10 日 於本公告日期，執行董事為連萬勇先生及楊秉華先生；非執行董事為晉斌先生、陳啟宇先生、 祖敬先生、邢永剛先生、馬躍先生、陳玉卿先生、文德鏞先生及李瑩女士；獨立非執行董事為 李培育先生、吳德龍先生、俞衛鋒先生、石晟昊先生及陳威如先生。 1 國藥控股股份有限公司（「本公司」）董事會（「董事會」）謹此宣佈，將於 2026 年 3 月 20 日（星期五）舉行董事會會議，藉以考慮及批准（其中包括）本公司及其附屬公司截至 2025 年 12 月 31 日止十二個月之年度業績及宣派股息（如有）。 ...

Group 1 - Lazard Asset Management LLC increased its stake in China National Pharmaceutical Group (国药控股) by purchasing 17,353,148 shares at an average price of HKD 20.8997 per share, totaling approximately HKD 363 million [1][2] - Following the acquisition, Lazard's total shareholding in China National Pharmaceutical Group rose to 176,585,924 shares, increasing its ownership percentage from 11.87% to 13.16% [1][2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 國藥控股股份有限公司 呈交日期: 2026年3月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01099 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,341,810,740 | RMB | | 1 | RMB | | 1,341,810,740 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 1,341,810,740 | RMB | | | 1 RMB | | 1,341,810,740 | | 2. ...

Group 1 - Morgan Stanley increased its stake in China National Pharmaceutical Group (01099) by 347,233 shares at an average price of HKD 21.4135 per share, totaling approximately HKD 7.4355 million [1] - After the increase, the total number of shares held by Morgan Stanley is approximately 67,120,300, representing a 5% ownership stake [1]

Core Viewpoint - Morgan Stanley increased its stake in China National Pharmaceutical Group (01099) by 347,233 shares at an average price of HKD 21.4135 per share, totaling approximately HKD 7.4355 million, bringing its total holdings to about 67.1203 million shares, representing a 5% ownership [1] Summary by Category - **Investment Activity** - Morgan Stanley's recent purchase of 347,233 shares indicates a strategic investment move in China National Pharmaceutical Group [1] - The average purchase price of HKD 21.4135 per share reflects the current market valuation and investor confidence in the company [1] - **Ownership Structure** - Following the acquisition, Morgan Stanley's total shareholding in China National Pharmaceutical Group stands at approximately 67.1203 million shares [1] - The updated ownership percentage of 5% signifies a notable stake in the company, which may influence future corporate decisions and market perception [1]

Core Viewpoint - Morgan Stanley increased its stake in China National Pharmaceutical Group (01099) by acquiring 347,233 shares at an average price of HKD 21.4135 per share, totaling approximately HKD 7.4355 million, resulting in a new holding of about 67.1203 million shares, representing a 5% ownership stake [1] Group 1 - Morgan Stanley's acquisition of shares indicates confidence in China National Pharmaceutical Group's future performance [1] - The average purchase price of HKD 21.4135 per share reflects the current market valuation of the company [1] - The total investment of approximately HKD 7.4355 million signifies a strategic move to increase ownership in the company [1]

Group 1 - As of February 24, 116 stocks reached a 52-week high, with the top three being Pu Tian Communication Group (01720) at 41.67%, Mobi Development (00947) at 32.08%, and Wei Jun Group Holdings (01013) at 21.95% [1][2] - The closing prices for the top three stocks are as follows: Pu Tian Communication Group at 0.650, Mobi Development at 0.265, and Wei Jun Group Holdings at 0.900 [2] - Other notable stocks that reached new highs include KFM Jinde (03816) at 16.47%, Haobo International (08431) at 13.41%, and Jiantao Laminated Board (01888) at 11.11% [2] Group 2 - The 52-week low rankings show MIRXES-B (02629) with a low rate of -19.31%, followed by Zhong Shen Jian Ye (02503) at -11.69% and Fen Bi (02469) at -7.65% [5] - The closing prices for the stocks at their 52-week lows include MIRXES-B at 18.000, Zhong Shen Jian Ye at 0.380, and Fen Bi at 1.590 [5] - Other stocks with significant declines include XI Er Nan Samsung (07347) at -7.10% and Yi He Holdings (01662) at -6.92% [5]

Core Viewpoint - China National Pharmaceutical Group (国药控股) experienced a decline on February 20, 2026, primarily due to short-term market sentiment, liquidity factors, and industry environment [1] Stock Performance - On February 20, the stock opened at HKD 20.60, down 4.1% from the previous closing price of HKD 21.48, with an intraday low of HKD 20.60. The closing price was HKD 20.98, reflecting a daily decline of 2.33% and a trading volume of approximately HKD 1.00 billion. The Hang Seng Index fell by 1.10%, with the pharmaceutical distribution sector declining by 5.13%, making China National Pharmaceutical Group one of the worst performers among Hang Seng Index constituents [2] Reasons for Stock Price Movement - Liquidity vacuum amplified selling pressure: The southbound trading (港股通) was closed on that day, preventing mainland funds from entering the market, leading to weak buying interest. A small amount of selling pressure caused a rapid decline in stock price, particularly evident in the pharmaceutical sector [3] - Industry policy and performance expectations were lackluster: No positive developments were observed in the pharmaceutical industry during the Spring Festival holiday, and concerns about policy adjustments, such as volume-based procurement, persisted. Additionally, the company's revenue for the first three quarters of 2025 decreased by 2.47%, although net profit slightly increased by 0.53%, leading to investor skepticism regarding short-term performance improvement [3] - Weight stocks dragged down and sector rotation occurred: Funds shifted from high-valuation sectors like pharmaceuticals and technology to defensive sectors such as energy and real estate, resulting in concentrated selling of China National Pharmaceutical Group as a pharmaceutical heavyweight. Concurrently, major tech stocks like Baidu and Alibaba also experienced significant declines, exacerbating market risk aversion [3] - External market transmission: Chinese concept stocks in the U.S. experienced widespread declines during the Spring Festival holiday, leading to a correction in the Hong Kong market. This was compounded by delayed expectations for U.S. Federal Reserve interest rate cuts and heightened geopolitical risks in the Middle East, putting pressure on global growth stock valuations [3] Capital and Technical Analysis - Capital flow: Southbound funds have been consistently reducing holdings, with a net reduction of 3.45 million shares on February 12 and a cumulative net reduction of 33.64 million shares over the past 20 trading days. However, Lazard Asset Management increased its holdings by 1.163 million shares on February 2, raising its stake to 11.06% [4] - Technical indicators: The stock price fell below the 20-day moving average (HKD 21.037), with the MACD histogram turning negative at -0.041 and the KDJ J-line dropping to 53.64, indicating weak short-term momentum [4] Future Development - Recent strategic actions include a partnership with Betta Pharmaceuticals (贝达药业) focused on supply chain optimization as of January 4, 2026. However, the medical device distribution business continues to be impacted by centralized procurement, and overall performance recovery will depend on subsequent policy and demand changes [5]